Gossamer Bio Announced Presentation Of Results Of TORREY FRI Sub-Study At The European Respiratory Society International Congress 2023
Gossamer Bio Announced Presentation Of Results Of TORREY FRI Sub-Study At The European Respiratory Society International Congress 2023
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Professor of Pulmonary and Critical Care Medicine at Stanford University, will present the data during a session on novel treatments in pulmonary hypertension management on Sunday, September 10th.
專注於開發和商業化治療肺動脈高壓（PAH）的臨床階段生物製藥公司Gossamer Bio, Inc.（納斯達克股票代碼：GOSS）今天宣佈，其功能性呼吸成像（FRI）子研究（FRI）的數據將在歐洲呼吸系統會議上公佈，該研究成功開展的賽魯替尼治療多環芳烴患者的2期TORREY研究 2023 年國際學會大會。斯坦福大學肺部和重症監護醫學教授羅漢姆·扎馬尼安博士將在9月10日星期日舉行的肺動脈高壓管理新療法會議上介紹這些數據。
譯文內容由第三人軟體翻譯。